What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective.
2019-nCoV Vaccine mRNA-1273
Ad26COVS1
/ therapeutic use
BNT162 Vaccine
/ therapeutic use
COVID-19
/ prevention & control
COVID-19 Vaccines
/ therapeutic use
ChAdOx1 nCoV-19
/ therapeutic use
Gastroenterology
Gastrointestinal Neoplasms
/ therapy
Humans
Inflammatory Bowel Diseases
/ therapy
Liver Diseases
/ therapy
SARS-CoV-2
Coronavirus
endoscopy
prevention
public health
vaccine
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
21
01
2021
accepted:
01
03
2021
pubmed:
9
6
2021
medline:
4
2
2022
entrez:
8
6
2021
Statut:
ppublish
Résumé
The novel Coronavirus (SARS-CoV-2) has caused almost 2 million deaths worldwide. Both Food and Drug Administration and European Medicines Agency have recently approved the first COVID-19 vaccines, and a few more are going to be approved soon. Several different approaches have been used to stimulate the immune system in mounting a humoral response. As more traditional approaches are under investigation (inactivated virus vaccines, protein subunit vaccines, recombinant virus vaccines), more recent and innovative strategies have been tried (non-replicating viral vector vaccines, RNA based vaccines, DNA based vaccines). Since vaccinations campaigns started in December 2020 in both the US and Europe, gastroenterologists will be one of the main sources of information regarding SARS-CoV 2 vaccination for patients in their practice, including vulnerable patients such as those with Inflammatory Bowel Disease (IBD), patients with chronic liver disease, and GI cancer patients. Thus, we must ourselves be well educated and updated in order to provide unambiguous counseling to these categories of vulnerable patients. In this commentary, we aim to provide a comprehensive review of both approved COVID-19 vaccines and the ones still under development, and explore potential risks, benefits and prioritization of vaccination.
Sections du résumé
BACKGROUND
The novel Coronavirus (SARS-CoV-2) has caused almost 2 million deaths worldwide. Both Food and Drug Administration and European Medicines Agency have recently approved the first COVID-19 vaccines, and a few more are going to be approved soon.
METHODS
Several different approaches have been used to stimulate the immune system in mounting a humoral response. As more traditional approaches are under investigation (inactivated virus vaccines, protein subunit vaccines, recombinant virus vaccines), more recent and innovative strategies have been tried (non-replicating viral vector vaccines, RNA based vaccines, DNA based vaccines).
RESULTS
Since vaccinations campaigns started in December 2020 in both the US and Europe, gastroenterologists will be one of the main sources of information regarding SARS-CoV 2 vaccination for patients in their practice, including vulnerable patients such as those with Inflammatory Bowel Disease (IBD), patients with chronic liver disease, and GI cancer patients.
CONCLUSIONS
Thus, we must ourselves be well educated and updated in order to provide unambiguous counseling to these categories of vulnerable patients. In this commentary, we aim to provide a comprehensive review of both approved COVID-19 vaccines and the ones still under development, and explore potential risks, benefits and prioritization of vaccination.
Identifiants
pubmed: 34102015
doi: 10.1002/ueg2.12103
pmc: PMC8242672
doi:
Substances chimiques
Ad26COVS1
JT2NS6183B
COVID-19 Vaccines
0
NVX-CoV2373 adjuvated lipid nanoparticle
2SCD8Q63PF
ChAdOx1 nCoV-19
B5S3K2V0G8
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
787-796Informations de copyright
© 2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC. on behalf of United European Gastroenterology.
Références
Gastrointest Endosc. 2019 Apr;89(4):818-824
pubmed: 30391253
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
J Hosp Infect. 2006 Oct;64(2):100-14
pubmed: 16916564
N Engl J Med. 2020 Dec 31;383(27):2684-2686
pubmed: 33326716
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
United European Gastroenterol J. 2021 Sep;9(7):787-796
pubmed: 34102015
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):156-158
pubmed: 33444545
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1533-1540.e8
pubmed: 30557713
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Ann Oncol. 2012 Feb;23(2):450-7
pubmed: 21576285
CA Cancer J Clin. 2017 Sep;67(5):398-410
pubmed: 28753241
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):218-224
pubmed: 33508241
Liver Int. 2021 Apr;41(4):720-730
pubmed: 33351265
Trials. 2020 Oct 15;21(1):853
pubmed: 33059771
JAMA Netw Open. 2020 Jun 1;3(6):e2011335
pubmed: 32525549
MMWR Morb Mortal Wkly Rep. 2020 Dec 11;69(49):1857-1859
pubmed: 33301429
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Antivir Ther. 2007;12(7):1107-13
pubmed: 18018769
J Hepatol. 2020 Nov;73(5):1063-1071
pubmed: 32526252
Gut. 2012 Mar;61(3):385-91
pubmed: 21757451
J Autoimmun. 2020 Nov;114:102511
pubmed: 32713677
Inflamm Bowel Dis. 2013 Mar;19(3):554-8
pubmed: 23380936
Gut. 2020 Oct;69(10):1832-1840
pubmed: 32571972
Med Oncol. 2002;19(2):71-8
pubmed: 12180483
Endoscopy. 2020 Oct;52(10):871-876
pubmed: 32356282
Lancet Infect Dis. 2019 Jun;19(6):e188-e199
pubmed: 30744964
Science. 2020 Jul 3;369(6499):77-81
pubmed: 32376603
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830861
Surg Endosc. 2021 Nov;35(11):6212-6219
pubmed: 33140149
Int J Infect Dis. 2020 Nov;100:483-489
pubmed: 32920233
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Am J Gastroenterol. 2010 Jan;105(1):148-54
pubmed: 19755964
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
BMJ Open. 2019 Sep 6;9(9):e031070
pubmed: 31494620
Gastroenterology. 2020 Jul;159(1):363-366.e3
pubmed: 32283102
Cancer Discov. 2021 Feb;11(2):233-236
pubmed: 33355178
Cancer. 2021 May 1;127(9):1459-1468
pubmed: 33378122
Ann Oncol. 2018 Jun 1;29(6):1354-1365
pubmed: 29688266
Gut. 2021 Mar;70(3):531-536
pubmed: 32660964
Lancet Infect Dis. 2021 Jan;21(1):39-51
pubmed: 33069281
Gut. 2020 Nov;69(11):1925-1927
pubmed: 32321857
Gastroenterology. 2020 Aug;159(2):481-491.e3
pubmed: 32425234
World J Gastroenterol. 2005 Oct 21;11(39):6159-64
pubmed: 16273643
Lancet. 2020 Sep 26;396(10255):887-897
pubmed: 32896291
Front Microbiol. 2019 Aug 02;10:1781
pubmed: 31428074
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Nature. 2021 Feb;590(7844):E26
pubmed: 33469216
J Med Virol. 2021 Feb;93(2):775-785
pubmed: 32667699
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nat Rev Drug Discov. 2018 Apr;17(4):261-279
pubmed: 29326426
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Clin Res Hepatol Gastroenterol. 2020 Apr;44(2):126-134
pubmed: 31607643
Nat Rev Immunol. 2020 Jun;20(6):347-348
pubmed: 32346094
N Engl J Med. 2020 Dec 10;383(24):2320-2332
pubmed: 32877576
N Engl J Med. 2021 Feb 18;384(7):643-649
pubmed: 33378605
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Liver Int. 2021 Aug;41(8):1824-1831
pubmed: 33534931
Adv Virus Res. 2016;96:245-286
pubmed: 27712626
Hepatology. 2021 Aug;74(2):1049-1064
pubmed: 33577086
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Br J Cancer. 2011 May 24;104(11):1670-4
pubmed: 21540859
Cochrane Database Syst Rev. 2018 Feb 01;2:CD008983
pubmed: 29388675
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019 Mar;11(2):e1530
pubmed: 29726120
Gastrointest Endosc. 2020 Jul;92(1):192-197
pubmed: 32179106
Emerg Infect Dis. 2004 Feb;10(2):269-76
pubmed: 15030696
Expert Rev Vaccines. 2019 Dec;18(12):1229-1242
pubmed: 31779496
Annu Rev Microbiol. 2019 Sep 8;73:529-557
pubmed: 31226023
J Hosp Infect. 2018 Jun;99(2):169-174
pubmed: 29225054
Clin Infect Dis. 2014 Feb;58(3):309-18
pubmed: 24421306
J Hepatol. 2021 Apr;74(4):944-951
pubmed: 33563499
N Engl J Med. 2021 Feb 18;384(7):619-629
pubmed: 33232588
Lancet. 2020 Mar 14;395(10227):848-850
pubmed: 32151326
Ann Hematol. 2021 Feb;100(2):383-393
pubmed: 33159569
Science. 2020 Jul 3;369(6499):50-54
pubmed: 32358202
Inflamm Bowel Dis. 2012 Jan;18(1):34-40
pubmed: 21337671
Gut. 2020 Jul;69(7):1335-1342
pubmed: 32303609
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Lancet Infect Dis. 2019 Jun;19(6):e200-e212
pubmed: 30744963
BMC Infect Dis. 2016 May 04;16:192
pubmed: 27142774
Int Immunopharmacol. 2021 Jan;90:107247
pubmed: 33307513
Dig Dis Sci. 2016 Oct;61(10):2972-2976
pubmed: 27557706